SCHEMBL4916014

SCHEMBL4916014

CCOC(=O)c1cccc(Nc2nc(C)c(C(=O)N(OCc3ccccc3)C3CCCC3)s2)c1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.52
RAB9A P51151 5/20 0.52
NPC1 O15118 4/20 0.52
HPGD P15428 2/20 0.52
KDM4E B2RXH2 3/20 0.49
ALDH1A1 P00352 3/20 0.49
DHODH Q02127 8/20 0.48
SMN1; SMN2 Q16637 3/20 0.45
CSNK1D P48730 1/20 0.44
CDC25B P30305 2/20 0.44
POLB P06746 1/20 0.43
TP53 P04637 2/20 0.42
TSHR P16473 1/20 0.42
CDC25A P30304 1/20 0.42
CDC25C P30307 1/20 0.42
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4916010 0.80 MAPT (0.50) MAPTRAB9ANPC1HPGDKDM4E
SCHEMBL4916008 0.80 MAPT (0.50) MAPTRAB9ANPC1HPGDKDM4E
SCHEMBL4914875 0.78 MAPT (0.69) MAPTRAB9ANPC1HPGDKDM4E
SCHEMBL4926288 0.78 NPC1 (0.44) RAB9ANPC1KDM4EALDH1A1SMN1; SMN2
SCHEMBL5353006 0.76 MAPT (0.38) MAPTRAB9ANPC1HPGDKDM4E
SCHEMBL2885791 0.70 MAPT (1.00) MAPTRAB9ANPC1HPGDKDM4E
SCHEMBL12296366 0.69 MAPT (0.79) MAPTRAB9ANPC1HPGDKDM4E
SCHEMBL12158128 0.69 MAPT (0.71) MAPTRAB9ANPC1HPGDKDM4E
SCHEMBL7107744 0.67 CDC25B (0.69) MAPTRAB9ANPC1HPGDKDM4E
SCHEMBL14184685 0.66 MEN1 (0.49) MAPTRAB9ANPC1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080125432-A1 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family DEVGEN NV (BE) 2008-05-29 US claimed
EP-1819330-A1 5-CARBOXAMIDO SUBSTITUED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE KV FAMILY Devgen N.V. (BE) 2007-08-22 EP claimed
WO-2006058905-A1 5-CARBOXAMIDO SUBSTITUTED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE Kv FAMILY DEVGEN NV (BE) 2006-06-08 WO claimed
US-20080125432-A1 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family DEVGEN NV (BE) 2008-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125432-A1 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family KCNA5, KCNA1, KCNJ2 MAPT 1729/4885RAB9A 1327/4885NPC1 1803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.